On September 28, Beijing time, Biogen and Eisai, foreign companies dedicated to the R&D of Alzheimer’s disease (AD) drugs, announced that its new AD drug Lecanemab Phase III clinical trial met its primary endpoint, which means that the drug can effectively improve patients’ cognitive ability and slow down the progression of AD. Lecanemab is the first beta-amyloid (Aβ) antibody to achieve positive results in a confirmatory Phase […]
The first subject in the phase III clinical trial of lutetium Lu 177 dotatate, the first targeted therapeutic radiopharmaceutical developed independently by Sinotau, was successfully randomized on September 22, 2022 at the First Medical Center of the Chinese PLA General Hospital which is the group leader unit, and successfully completed dosing on September 24, marking another milestone for this project. About Lutetium Lu 177 Dotatate Lutetium Lu 177 dotatate, the first nuclide therapeutic drug developed […]
On July 8, 2022, Sinotau’s new drug application for florbetaben F18 injection (NeuraceqTM) was accepted by CDE. Neuraceq is a brain β-amyloid (Aβ) positron emission tomography (PET) imaging agent developed by Life Molecular Imaging (LMI) in Germany. It allows for the accurate measurement of β-amyloid (Aβ) levels in the brain of adult patients through PET/CT […]
A few days ago，Guangdong Sinotau Molecular Imaging Technology Co., Ltd. has successfully obtained the “radiation safety license”. By this point of time，Guangdong Sinotau Molecular Imaging Technology Co., Ltd. has formally possessed the qualification of cyclotron operation and the production, use and sales of nuclides, which also creates the conditions for the smooth promotion of the company’s […]
Petach Tikva, Israel, and Beijing China 19 Oct 2021 – Isotopia Molecular Imaging and Sinotau Pharmaceuticals, a global radiopharmaceutical developer and producer, are pleased to announce a strategic collaboration for the supply of the medical radioisotope non-carrier-added 177Lu to support the clinical development of Sinotau pipeline. The Chinese Radiopharmaceutical market has been driven by the continuous innovation efforts of industrial leaders like Sinotau […]
Recently, Sinotau Pharmaceutical Group announced it has closed an 320 million RMB D+ financing, which was jointly invested by China Life Private Equity and Centurium Capital, and continued to be followed by the existing shareholders, Tianjin Panya Equity Investment Fund Partnership(L.P.) and Deyi Investment Management (Beijing) Co., Ltd., and a lot of help and support from WinX Capital. Previously, in February 2021, Sinotau […]
Sinotau Pharmaceuticals has announced an agreement with HTA CO. LTD for launching a new β-amyloid imaging agent for Alzheimer’s disease in China. “This agreement will greatly contribute to the successful launch of future products in China. It is expected that this new product will be used to treat patients by delivering the latest diagnostic technologies […]
Oct. 16th, 2017. (BUSINESS WIRE) – Cerveau Technologies, Inc. has announced a research collaboration agreement with Janssen Pharmaceuticals, Inc. for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, which are made up of aggregated […]
Sep. 14th, 2017. (BUSINESS WIRE) – Cerveau Technologies, Inc. has announced a research collaboration agreement with H. Lundbeck A/S for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein […]
Jun. 26th, 2017. (BUSINESS WIRE) – Cerveau Technologies Inc. today announced a research collaboration with the NYU Langone Medical Center to support various research projects studying the stages of Alzheimer’s Disease and other Neurodegenerative diseases. These research projects will utilize an investigational imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for […]
Jun. 16th, 2017, (BUSINESS WIRE) – Cerveau Technologies, Inc. has announced that the United States Food and Drug Administration has cleared their IND for [18F]MK-6240, an investigational tau imaging agent. Cerveau plans to work with partners to study the use of this product in Positron Emission Tomography (PET) scans for assessing the status and progression of […]
May. 24th, 2017. (BUSINESS WIRE) – Cerveau Technologies, Inc. today announced a research collaboration with the Clinical Imaging Research Centre (CIRC), a joint venture by the Agency for Science, Technology and Research (A*STAR) and the National University of Singapore (NUS), to support various research projects studying the stages of Alzheimer’s Disease and other Neurodegenerative disease. […]